Suvratoxumab

Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type) . Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) [1][2][3].

Product Specifications

CAS Number

[1629620-18-3]

Product Name Alternative

MEDI4893

UNSPSC

12352203

Target

Bacterial

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/suvratoxumab.html

Purity

98.79

Solubility

10 mM in DMSO

Smiles

[Suvratoxumab]

Molecular Weight

(145.54 kDa)

References & Citations

[1]Hua L, et al. MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model. Antimicrob Agents Chemother. 2015 Aug;59 (8) :4526-32. |[2]Yu XQ, et al. Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrob Agents Chemother. 2016 Dec 27;61 (1) :e01020-16. |[3]Oganesyan V, et al. Mechanisms of neutralization of a human anti-α-toxin antibody. J Biol Chem. 2014 Oct 24;289 (43) :29874-80.